# From mechanism to management: CEREMAST perspectives on the intersection of HαT and clonal mast cell disorders

## TL;DR

This paper discusses how hereditary alpha-tryptasemia (HαT) affects the diagnosis and management of clonal mast cell disorders, highlighting unresolved questions and the French Reference Center's clinical approach.

## Contribution

The paper presents the clinical position and approach of CEREMAST on integrating HαT into the management of clonal mast cell activation disorders.

## Key findings

- HαT is highly prevalent among patients with clonal mast cell activation disorders.
- HαT is associated with elevated baseline serum tryptase levels, impacting diagnosis and monitoring.
- HαT increases the risk of severe anaphylaxis in these patients.

## Abstract

Since its initial description ten years ago, numerous studies have contributed to a better understanding of the role of hereditary alpha-tryptasemia (HαT) in the diagnosis and management of patients with clonal mast cell activation disorders (cMCADs). These studies have highlighted the high prevalence of HαT among cMCADs patients, the associated elevation in baseline serum tryptase levels—which can influence both diagnosis and disease monitoring—and distinct clinical features, notably an increased risk of severe anaphylaxis. As a result, screening for HαT has become an integral part of the diagnostic work-up in patients with cMCADs. However, several key questions remain unresolved: Why is HαT more prevalent among cMCADs patients? How can we accurately distinguish between HαT and cMCADs during the diagnostic process? And how does the presence of this genetic trait influence the clinical management of cMCADs? In this article, we present the position and clinical approach of the French National Reference Center for Mastocytosis (CEREMAST).